Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

17 beta-hydroxysteroid dehydrogenases type 13 inhibitor - Enanta Pharmaceuticals

X
Drug Profile

17 beta-hydroxysteroid dehydrogenases type 13 inhibitor - Enanta Pharmaceuticals

Alternative Names: 17β-Hydroxysteroid dehydrogenases inhibitors - Enanta Pharmaceuticals; HSD17B13 inhibitors - Enanta Pharmaceuticals

Latest Information Update: 16 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enanta Pharmaceuticals
  • Class Anti-inflammatories; Hepatoprotectants; Small molecules
  • Mechanism of Action 17-hydroxysteroid dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Liver disorders

Most Recent Events

  • 21 Jun 2023 Pharmacodynamics data from preclinical studies in Liver disorders presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)
  • 02 Sep 2022 Pharmacodynamics data from a preclinical studies in Liver disorders presented at the International Liver Congress
  • 22 Jun 2022 17 beta-hydroxysteroid dehydrogenases type 13 inhibitors - Enanta Pharmaceuticals is available for licensing as of 22 Jun 2022. www.enanta.com 809360318
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top